

9<sup>th</sup> World Conference



# TARGETING Phage Therapy

JUNE 9 · 10 2026  
VALENCIA · SPAIN



PROGRAM

PHAGE  
THERAPY  
2026

# 9<sup>th</sup> World Congress Targeting Phage Therapy 2026

June 9 - 10, 2026 – Valencia, Spain

## Day 1 - June 9, 2026

- 8h00 Welcoming of attendees & Badge Distribution
- 8h50 Opening Remarks by **Sandra Sevilla**, President, CECAV, Spain
- 9h00 **Keynote Speech**



**Turning Evolution into Therapy: A New Strategy to Fight Antibiotic-Resistant Infections**  
**Benjamin K. Chan**, Yale University, USA

### Session 1 – Advances in Phage Therapy: From Mechanisms to Clinical Translation



9h45 **Advancing Phage Therapy for Chronic Infections:  
From Experimental Evidence to Clinical Use**  
**Joana Azeredo**, University of Minho, Portugal



10h15 **Bacteriophages Redesigned: Engineering of Next-Generation  
Phage Therapeutics and Diagnostics**  
**Martin J. Loessner**, ETH Zürich, Switzerland

10h45 – 11h30 Coffee Break, Networking and Poster Sessions



11h30 **The Human Virome in Chronic Infection:  
What Patient Phages Teach Us About Therapeutic Phage Design**  
**Katrine Whiteson**, UC Irvine, USA

12h00 Short Oral presentations

12h30 - 14h00 Lunch Break, Networking, Poster, Group Photo

### Session 2 – Phages Across One Health: Animal, Food, and Industry



14h00 **Phage for Sustainable and Scalable Infection Control in Aquaculture**  
**Adelaide Almeida**, Universidade de Aveiro, Portugal



14h30 **Phage Therapy in Livestock Disease Models: Lessons for Animal and Human Health**  
**Robert Atterbury**, University of Nottingham, United Kingdom

15h00 Discussion

15h30 - Coffee Break, Networking, Poster



16h15 **Nasopharyngeal Phages: The Silent Players in Piglet Health**  
**Oscar Mencía-Ares**, *Universidad de León, Spain*

16h45 Short Oral presentations

18h00 End of Conference Day One

20h00 Speakers' Dinner (reserved for ticket holders)

## Day 2 - June 10, 2026

8h00 Welcoming of attendees

### Session 3 – Production, Regulation, and Market Access



8h30 **Personalized Bacteriophage Therapy in Germany and Beyond – A Consensus-Based Guideline**  
*Annika Y. Classen, Cologne University Hospital, Germany*



9h00 **France launches its first public GMP Platform to produce large batches of Therapeutic Phages at affordable scale**  
*Frédéric Laurent, Hospices Civils de Lyon, France*



9h30 **The Qualified Presumption of Safety (QPS) Qualification of Lytic Bacteriophages: Scientific Criteria and Regulatory Perspectives**  
*Juan Evaristo Suárez, Universidad de Oviedo, Spain*

10h00 Short Oral presentations

**10h30 Coffee Break, Networking and Poster Sessions**



11h15 **From Bioreactor to Patient: Scalable Manufacturing and Delivery of Therapeutic Phages**  
*Danish J. Malik, Loughborough University, United Kingdom*

11h45 Short Oral presentations

**12h30 - 13h30 Lunch Break, Networking and Poster**

### Session 4 – Innovation Forum: Building the Future of Phage Therapy



13h30 **Chronic Respiratory Infections in the Inflamed Lung: Host–Pathogen Interactions and Opportunities for Phage Therapeutics**  
*Paula Zamora, University of Kansas Medical Center, USA*



14h00 **Phage–Pseudomonas Interactions: Changes in Host Physiology and the Potential Impact on Phage Therapy**  
*Piotr Golec, University of Warsaw, Poland*



14h30 **Personalized Phage Therapy at the Hannover Medical School: Barriers, Challenges, and Next Steps**  
*Evgenii Rubalskii, Medizinische Hochschule Hannover, Germany*

15h00 **Innovation Forum: From Scientific Concepts to Translational Impact**

Selected academic and industrial projects will be presented during a dedicated Innovation Forum and evaluated by the Scientific Board Jury for their scientific rationale, technological originality, translational potential, and clinical or industrial impact.

Submit your innovation by selecting the “**Award Category**” during submission.



16h00

**Strategic Roundtable Chaired by Pilar Domingo-Calap**

**Targeting Phage Therapy Beyond 2026: From Promise to Clinical Reality**

A forward-looking discussion bringing together leading speakers and chairs to define the next priorities for phage therapy.

Each contributor will present one strategic direction to accelerate translation, from phage selection and engineering to clinical protocols, regulation, GMP production, and market access.

**With insights from: Benjamin K. Chan, Robert Atterbury, Frédéric Laurent, Barbara Brenner, and other invited experts.**

17h00 **Concluding Note** by Pilar Domingo-Calap

17h00 **Awards of Targeting Phage Therapy 2026**

- *Scientific Innovation Award*
- *Clinical Impact Award*
- *Industrial & Translational Innovation Award*

17h10 **Closing Perspective:** Turning Phage Therapy Into a Scalable Clinical Reality  
Sandra Sevilla and Marvin Edeas

**17h20 Drinks and Appetizer – Networking**

17h20 **End of Targeting Phage Therapy 2026**

For more information, please visit: [www.phagetherapy-site.com](http://www.phagetherapy-site.com)